 |
市場調査レポート
商品コード
968265
世界の腫瘍溶解性ウイルス免疫療法の市場規模調査：タイプ別、用途別および地域別予測（2020年～2027年）Global Oncolytic Virus Immunotherapy Market Size study, by Type (Engineering Oncolytic Viruses and Wild-Type Oncolytic Viruses), By Application (Hospitals, Clinics and Ambulatory Surgical Centers) and Regional Forecasts 2020-2027 |
||||||
| 世界の腫瘍溶解性ウイルス免疫療法の市場規模調査：タイプ別、用途別および地域別予測（2020年～2027年） |
|
出版日: 2020年10月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
|
世界の腫瘍溶解性ウイルス免疫療法の市場規模は2019年に約6,890万米ドルであり、2020年から2027年の予測期間にわたって12.00％を超える成長率で成長すると予想されています。医学と技術の進歩により、腫瘍溶解性ウイルス免疫療法は一貫した成長を遂げています。免疫系を含む腫瘍生物学の3層を主に対象とする一連の免疫療法は、有望な最終結果によりかなりの牽引力を獲得しています。腫瘍溶解性ウイルス免疫療法を用いた初期段階の臨床試験中の有望な結果は、市場の全体的な成長を後押しする上で不可欠な役割を果たしています。進行中の臨床試験では、腫瘍溶解性ウイルス免疫療法の進歩と腫瘍溶解性ウイルス免疫療法への規制措置により、2020年から2027年の予測期間中に市場の成長が促進されます。ただし、臨床開発の後期段階での失敗は、2020年から2027年の予測期間中に市場の成長を妨げる可能性があります。
当レポートでは、腫瘍溶解性ウイルス免疫療法市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・用途別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。
Global Oncolytic Virus Immunotherapy Market is valued approximately USD 68.90 million in 2019 and is anticipated to grow with a healthy growth rate of more than 12.00 % over the forecast period 2020-2027. Due to advancements in medical science and technology, immunotherapy is at the helm of modern oncology care due to which the deployment of oncolytic virus immunotherapy has witnessed consistent growth. A spectrum of immunotherapies that primarily target three layers of tumor biology, including immune system and it has gained considerable traction owing to the promising end-results. Further, the development of anti-cancer treatment therapies has largely focused on delivering customized therapy to cellular targets. The promising outcomes during the early stage clinical trials with oncolytic virus immunotherapy is further expected to play an imperative tole in boosting the overall growth of the market. Also, the key players are focusing on strategies such as product launch, innovation and merger & acquisition to sustain themselves amidst fierce competition. Ongoing clinical trials, advancement in oncolytic virus immunotherapy along with the regulatory imposition on oncolytic virus immunotherapy would drive the growth of the market during the forecast period of 2020-2027. However, failure of these molecules in late stage of clinical developments may be leveling off for companies operating in the market which is hampering the growth of the market during the forecast period of 2020-2027.
The regional analysis of global Oncolytic Virus Immunotherapy market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region due to the owing to high prevalence of cancer, specifically melanoma cancer. Also, the dominance of the region is witnessed owing to the strong presence of leading manufacturers and high rate of manufacturer's sponsorship are contributing to greater availability of oncolytic virus immunotherapy in the region. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.
Major market player included in this report are:
Merck
Amgen
TILT Biotherapeutics
Oncorus
Sorrento Therapeutics
Shanghai Sunway Biotech
BioVex, Inc.
Cold Genesys, Inc.
DNAtrix Therapeutics
Genelux Corporation
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Engineering Oncolytic Viruses
Wild-Type Oncolytic Viruses
By Application:
Hospitals
Clinics
Ambulatory Surgical Centers
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2017, 2018
Base year - 2019
Forecast period - 2020 to 2027
Target Audience of the Global Oncolytic Virus Immunotherapy Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
比較リスト
